If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Menu closed
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Abasaglar ® (basal insulin glargine)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Abasaglar Summary of Product Characteristics (SmPC)
Abasaglar® (insulin glargine): Missed dose
In the event of a missed dose of Abasaglar, physicians may use their clinical discretion based on the patient's situation.
Detailed
Information
There
is no one rule on what to do in the event of a missed dose of
insulin, including IGlar.
Patients
with a missed dose of Abasaglar should :
test
their blood glucose and their urine for ketones as soon as any
symptoms of hyperglycaemia occur,1
For
patients who miss a dose of Abasaglar, physicians may use their
clinical discretion regarding resumption of dosing. Factors that may
be considered by physicians include :
the
wide spectrum of disease progression
individual
dosing ranges
time
from the missed dose, and
concomitant
medications.
References
1.
Abasaglar [package leaflet: information for the patient]. Eli Lilly
Nederland B.V., The Netherlands.
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com